FDA grants oNKord ® "orphan drug" for treating multiple myeloma

Multiple myeloma (MM) is the second most common blood cancer, accounting for 15% of blood cancer and 2% of all cancers.
alone, it affects more than 130,000 patients.
about 32,000 Americans are diagnosed with MM each year.
MM occurs in anti-infected plasma cells (a type of white blood cell) in the bone marrow, and these proliferating cancer cells are able to produce abnormal proteins.
, a leading biotech company, announced today that its oNKord® has been awarded the FDA's Orphan Drug Title (ODD) for the treatment of multiple myeloma (MM).
is ® first generation of Natural Killer (NK) cell immunotherapy at Glycostem.
AML patients will receive this treatment over the next few months as part of the AML I-IIa phase trial.
Phase II clinical trials in MM patients are expected to begin in 2021.
S. Glycostem CEO Troels Jordansen said, "Since 2012, we have been a pioneer in the development and manufacture of natural killer cell therapies for cancer treatment.
fda also granted ODD for treatment MM after obtaining ODD approval from fda and EMA treatment AML, which allows us to accelerate the entry of oNKord ® into the U.S. market."
.